Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-Targeted Cord Blood CAR-T Cells in R/R B-ALL
NCT07838714Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Ruijin Hospital. Primary endpoint: Dose-Limiting Toxicity at 14 days. Started May 2026; status: recruiting.
02
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07838714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838714.